1.22
-0.01 (-0.41%)
| Previous Close | 1.23 |
| Volume | 3,979,962 |
| Price / Earnings (Forward) | 65.36 |
| Price / Sales | 4.27 |
| Price / Book | 3.84 |
| 52 Weeks Range |
| Profit Margin | -119.54% |
| Operating Margin (TTM) | -42.18% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 12,927.30% |
| Total Debt/Equity (MRQ) | 45.40% |
| Current Ratio (MRQ) | 7.86 |
| Operating Cash Flow (TTM) | -204.34 M |
| Levered Free Cash Flow (TTM) | -142.38 M |
| Return on Assets (TTM) | -16.07% |
| Return on Equity (TTM) | -45.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Geron Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Average | 0.75 |
Select this tab to load the latest available analysis.
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 81.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ra Capital Management, L.P. | 30 Jun 2026 | 42,809,751 |
| Clearbridge Investments, Llc | 30 Jun 2026 | 19,648,853 |
| Eversept Partners, Lp | 30 Jun 2026 | 18,717,422 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SPIEGEL ROBERT J. | 1.23 | - | 6,351 | 7,812 |
| Aggregate Net Quantity | 6,351 | |||
| Aggregate Net Value ($) | 7,812 | |||
| Aggregate Avg. Buy ($) | 1.23 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SPIEGEL ROBERT J. | Director | 30 Sep 2026 | Acquired (+) | 6,351 | 1.23 | 7,812 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |